JUNO THERAPEUTICS INC

Inactive Instrument

Juno Therapeutics Inc Share Price

Equities

US48205A1097

Biotechnology & Medical Research

Chart Juno Therapeutics Inc

Duration

Period

Style

Latest news about Juno Therapeutics Inc

Takeda Pharmaceutical : Merits of any Takeda bid for Shire questioned, shares slide	29/03/18	RE
Takeda Pharmaceutical : Merits of any Takeda bid for Shire questioned, shares slide	29/03/18	RE
Takeda Pharmaceutical : Drugmaker Shire soars as Japan's Takeda considers bid	28/03/18	RE
Gilead Sciences : Sangamo in $3 billion gene-editing deal with Gilead	22/02/18	RE
Ablynx : Sanofi beats Novo to buy Ablynx for $4.8 billion in biotech M&A boom	30/01/18	RE
Stocks hit record as senators reach deal to end shutdown	22/01/18	RE
Ablynx : Biotech M&A takes off as Sanofi and Celgene spend $20 billion	22/01/18	RE
Biogen : Sanofi digs deep to buy U.S. haemophilia group Bioverativ for $11.6 billion	22/01/18	RE
Novartis : FDA panel backs Novartis' pioneering new cancer gene therapy	12/07/17	RE
Juno Therapeutics : Yahoo says about 32 million accounts accessed using 'forged cookies'	02/03/17	RE
Juno Therapeutics : Yahoo says about 32 million accounts accessed using 'forged cookies'	01/03/17	RE
Juno Therapeutics : Shares of Juno Therapeutics jump after FDA removes clinical hold on cancer drug trial	12/07/16	RE
Celgene : Wall Street lauds Celgene's $7.2 billion Receptos buy	15/07/15	RE
Celgene : to buy Receptos for $7.2 billion; gains promising drug	15/07/15	RE

Press releases Juno Therapeutics Inc

Juno Therapeutics : Celgene Receives Antitrust Clearance for Juno Acquisition	21/02/18	BU
WeissLaw LLP : Investigates Juno Therapeutics Inc. Acquisition	24/01/18	PR
JUNO THERAPEUTICS, INC. Former SEC Attorney Willie Briscoe Believes the Acquisition by Celgene Corporation May be Unfair to Shareholders	22/01/18	BU
Celgene Corporation : to Acquire Juno Therapeutics, Inc., Advancing Global Leadership in Cellular Immunotherapy	22/01/18	BU
JUNO THERAPEUTICS INVESTIGATION by Former Louisiana Attorney General: Kahn Swick & Foti, LLC Continues to Investigate the Officers and Directors of Juno Therapeutics, Inc. - JUNO	20/01/18	BU

More press releases

News in other languages on Juno Therapeutics Inc

Ablynx : Sanofi s'offre une nouvelle biotech en achetant Ablynx 3,9 milliards d'euros	29/01/18
Original-Research: Medigene AG (von EQUITS GmbH): Kaufen	23/01/18
Apple : Wall Street finit en hausse, accord sur le "shutdown"	22/01/18
BOURSE : Wall Street finit à des records après l'accord au Sénat mettant fin au "shutdown"	22/01/18
Barclays : Les Bourses européennes clôturent en hausse, le M&A éclipse le "shutdown"	22/01/18

Managers and Directors - Juno Therapeutics Inc

Managers	Title	Age	Since
Nicole Keith IRC	Investor Relations Contact	-	30/06/15
Jonathan Biller TRE	Treasurer	61	-
Katherine Reynolds Kelly SEC	Corporate Secretary	48	-

Members of the board	Title	Age	Since
Mark Alles BRD	Director/Board Member	64	-
Peter Kellogg BRD	Director/Board Member	67	-

Company Profile

Sector

Biotechnology & Medical Research

More about the company

Sector Bio Therapeutic Drugs

	1st Jan change	Capi.
VERTEX PHARMACEUTICALS INCORPORATED	+3.91%	109B
REGENERON PHARMACEUTICALS, INC.	+10.87%	105B
ARGENX SE	+1.28%	22.25B
BIONTECH SE	-13.14%	22.09B
GENMAB A/S	-7.05%	18.68B
WUXI APPTEC CO., LTD.	-38.36%	17.58B
BEIGENE, LTD.	-10.66%	16.85B
NEUROCRINE BIOSCIENCES, INC.	+3.75%	13.76B
SAREPTA THERAPEUTICS, INC.	+36.70%	12.46B

Bio Therapeutic Drugs

All transcripts on over 9000 companies, on the day they post their earnings!

Unlock them now!

fermer